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Abstract
The roots of Panax ginseng C. A. Meyer, known as Korean ginseng have been a valuable and important
folk medicine in the East Asian countries, such as China, Korea and Japan for about 2000 years. Panax
is derived from a word ‘‘panacea’’, which means cure-all diseases and longevity as well as physical
strength and resistance. As the use of traditional Chinese herbs as a food supply becomes more and more
popular in the western countries, sales of Panax ginseng are increasing in North America and Europe as
well as other parts of the world. Active constituents found in most ginseng species include ginsenosides,
polysaccharides, peptides, polyacetylenic alcohols and fatty acids. Major active components in Panax
ginseng are the ginsenosides, a group of saponins with triterpenoid dammarane structure. More than 30
ginsenosides have been isolated, and known compounds are identiﬁed but new compounds were eluci-
dated. Pharmacological eﬀects of ginseng have been demonstrated in cancer, diabetes mellitus, cardio-
vascular system, immune system and central nervous system including anti-stress and anti-oxidant
activity. We have focused this review on the eﬀect of ginseng on diabetes, anticancer activity and
cardiovascular system and chemical structures of ginsenosides. In addition, our recent biological study on
20(S)-ginsenoside Rg3 is also touched upon as follows. Multidrug resistance (MDR) has been a major
problem in cancer chemotherapy. In this study in vitro and in vivo modulations of MDR by 20(S)-
ginsenoside Rg3 (Rg3), a saponin characteristic of red ginseng, was investigated. In ﬂow cytometric
analysis using rhodamine 123 as an artiﬁcial substrate, Rg3 promoted accumulation of rhodamine 123 in
drug-resistant human ﬁbrocarcinoma KBV 20C cells in a dose-dependent manner, but it had no eﬀect on
parental KB cells. Additionally Rg3 inhibited [
3H]-vinblastine eﬄux and reversed MDR to DOX
(doxorubicin), COL, VCR (vincristine) and VP-16 in KBV20C cells. Reverse transcriptase-polymerase
chain reaction and immuno-blot analysis after exposure of KBV20C cells to Rg3 showed that inhibition
of drug eﬄux by Rg3 was due to neither repression of MDR1 gene expression nor P-glycoprotein (Pgp)
level. Photo-aﬃnity labeling study with [3H]-azidopine, however, revealed that Rg3 competed with [
3H]-
azidopine for binding to the Pgp demonstrating that G-Rg3 competed with anticancer drug for binding to
Pgp thereby blocking drug eﬄux. Furthermore, Rg3 increased life span in mice implanted with DOX-
resistant murine leukemia P388 cells in vivo and inhibited body weight increase signiﬁcantly. Further
clinical trial of Rg3 in reversal of Pgp-associated MDR is highly feasible.
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Introduction
The root of Panax ginseng is one of traditional and
folk medicines which has been used for many
therapeutic purposes in the oriental countries such
as Korea, China and Japan for thousands of years.
The source plant of ginseng is Panax ginseng C. A.
Meyer (Araliaceae), a herb with ﬂeshy roots which
grows wild in cool and shady forests extending
from Korea and North eastern China to far east-
ern Siberia. However, because wild ginseng is rel-
atively rare and very expensive, it has been
cultivated in Korea, China and Japan. Most of
commercially available ginseng is the root of Pa-
nax ginseng cultivated in Korea, the northeast
district of China and Japan. The medical eﬀects
described in the related reference books categorize
ginseng as a ‘‘mild’’ medication, a tonic that
strengthens, invigorates a weakened body. The
mainly physical ailments for which ginseng is said
to be eﬀective include headache, fatigue, dizziness,
nausea, asthma, hemorrhage and impotence. It is
further said to generally strengthen the viscera,
improve resistance to external disease- causing
agents, and improve the general physical condi-
tions and mental capacity. Modern scientiﬁc data
is substantiating many of these claims. Eminent
scholars from around the world have focused their
research their research into a question: which
substances in ginseng manifest such miraculous
eﬀects ? The research has made much progress, but
still insuﬃcient to fully uncover the mystery of
ginseng. In a noteworthy development in the
1960s, Sibata group identiﬁed the structures of
saponin and called them as ginsenosides (Shibata
et al., 1963a, b). Latest surveys show that saponins
account for about 3–4 % of Korean ginseng, and
more than 30 kinds of ginsenosides have been
found in it, double the number in ginseng of other
countries (Park, 1996). Considering that each of
these ginsenosides has diﬀerent pharmacological
activities, it becomes apparent that Korean gin-
seng might have a pharmacological eﬀectiveness
superior to those of any other. In this paper, we
review recent studies on the eﬀects of ginsenosides
on various diseases, particularly on diabetes,
hypertension and cancer. Ginseng improves glu-
cose homeostasis and insulin sensitivity. It exerts
cytotoxic and anti-metastatic activities against
various kinds of cancer cell lines, and induces
diﬀerentiation or apoptosis of several cancer cells.
Furthermore, ginsenoside has been reported to
have an anti-neoplastic eﬀect by enhancing im-
mune function. An anti-hypertensive eﬀect of
ginsenoside is shown to occur by the enhanced
synthesis and release of nitric oxide. In addition,
ginsenoside exerts anti-atherosclerotic and anti-
platelet eﬀects. This review provides useful infor-
mation on the pharmacological and clinical usage,
and also suggests a method to conduct further
study on ginseng to identify its potential eﬀects.
Structural property of ginsenoside
The history of scientiﬁc research on ginseng dates
back to 1854 when Garriques, an American sci-
entist, isolated a saponin from ginseng. However,
the actual introduction of ginseng to the West
happened after World War II. The chemical
structures of several ginseng saponins were char-
acterized in the late 1960s and further accelerated
scientiﬁc research on ginseng. Saponin compo-
nents are triterpenoidal dammarane glycosides,
named ginsenosides Rx according to their mobility
on TLC plates, with polarity decreasing from
index ‘‘a’’ to ‘‘h’’. Ginsenosides, known as sapo-
nins, are the major components of ginseng
(Figures 1, 2, 3 and 4). Ginsenosides possess
dammarane triterpenoidal skeleton with a modi-
ﬁed side chain at C-20 (Shibata et al., 1995; Hu-
ang, 1999). They diﬀer from one another by the
type of sugar moieties, their number and their site
of attachment. Among the saponins, the genuine
sapogenins, protopanaxadiol and protopanaxatri-
ol have been identiﬁed as dammar-24-ene-3b, 12b,
20(S)-triol and dammar-24-ene-3b, 6a 12b, 20(S)-
tetrol, respectively (Shibata et al., 2001).
Ginsenosides of red and white ginsengs
The root of Panax ginseng is steamed and dried to
prepare red ginseng, while the peeled roots dried
without steaming are designated as white ginseng.
The commercially available ginseng roots are
classiﬁed into two forms, red and white ginsengs. It
was reported that all of the saponins found in white
ginseng were isolated in similar yields from red
ginseng, while some partly deglycosylated saponins
such as ginsenosides Rh1, Rh2 and Rg3 are
obtained from red ginseng as artifacts produced
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during steaming (Kitagawa et al., 1983). In addi-
tion, two minor saponins were also isolated only
from red ginseng, two being designated as ginse-
nosides Rs1 and Rs2 (Kasai et al., 1983). Stepwise
deglycosylated compounds such as compound K
and 20(S)-protopanaxatriol can be generated
through metabolic transformation by human
intestinal bacteria (Hasegawa et al., 1996). Ginse-
noside Rg2 is converted into 20(S)-protopanaxat-
riol via ginsenoside Rh1. The binding of the sugar
has been shown to have inﬂuence on biological
activity. Rh1 and Rh2 are structurally similar, but
have diﬀerent activity. Ginsenoside Rh2 decreased
growth of B16-BL6 melanoma cells, and stimu-
lated melanogenesis and cell-to-cell adhesiveness.
However, Rh1 had no eﬀect on cell growth and
cell-to-cell adhesiveness, but stimulated melano-
genesis (Odashima et al., 1985). Although both
Rh2 and Rh3 induced diﬀerentiation of promyelo-
cytic leukemia HL-60 cells into morphological and
functional granulocytes, the potency of Rh2 was
higher (Kim et al., 1998). Another factor that
contributes to structural diﬀerence between ginse-
nosides is stereochemistry at C-20. Although both
20(S)- and 20(R)-ginsenoside Rg2 inhibit acetyl-
choline-evoked secretion of catecholamines from
cultured bovine adrenal chromaﬃn cells, the
20(S) isomer shows a greater inhibitory eﬀect (Kudo
et al., 1998). For newdammarane glycosides named
ginsenosides Rg5, Rh4, Rs3 and Rf2 have been
recently isolated fromKorean red ginseng and their
chemical structures have been elucidated by chem-
ical and spectroscopic methods, as 3-O-[b-D-gluco-
pyranosyl (1 ﬁ 2))b-D-glucopyranosyl]dammar-20
(22), 24-diene-3b,12b-diol (ginsenoside Rg5), 6-O-
b-D-glucopyranosyl-dammar-20(22), 24-diene-3b,
Figure 1. Chemical structures of protopanaxadiol ginsenosides.
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6a,12b-triol (ginsenoside Rh4), 3-O-[6¢¢-O-acetyl-b-D-
glucopyranosyl(1 ﬁ 2))b-D-glucopyranosyl] 20(S)-
protopanax adiol(ginsenoside Rs3) and 6-O-[a-L-
rhamnopyranosyl(1 ﬁ 2))b-D-glucopyranosyl]da
mmarane-3b,6a,12b,20(R),25-pentol (ginsenoside
Rf2) (Park et al., 1998) (Figures 1 and 4).
Metabolism of ginseng saponins by human
intestinal bacteria
Crude drugs in herbal prescriptions con-
tain many b-glycosides. Orally administered b-
glycosides must meet gastric juice, digestive and
bacterial enzymes in the gastrointestinal tract.
Therefore, plant b-glycosides may act as natural
prodrugs (Kobashi, 1998), which can be trans-
formed to active metabolites after oral adminis-
tration and ﬁnally induce biological activities. The
decomposed products taken from the stomach of
rats given a gastric bolus of ginsenoside Rb2 dif-
fered from those produced by 0.1 N HCl (Han
et al., 1982), and Rb2 was found to be hardly
decomposed by gastric juice with the exception of
slight oxygenation (Karikura et al., 1991a, b).
Certain ginsenosides such as Rb1 and Rg1 are
poorly absorbed after injection (Odani et al.,
1983). The metabolism of ginsenosides by human
intestinal bacteria was examined. The oligosac-
charides connected to the C-3 or C-20 hydroxy
group of the aglycone are cleaved stepwise from
the terminal sugar by bacterial hydrolysis. The
Figure 2. Chemical structures of protopanaxatriol ginsenosides.
Figure 3. Chemical structures of oleanane ginsenoside.
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main metabolic pathways are supposed as shown
in Figure 5. Protopanaxadiol type saponins (gin-
senosides Rb1, Rb2, Rc and Rd) were hydrolyzed
to compound K(C-K) by intestinal ﬂora (Karikura
et al., 1991a, b) and the bacteria capable of
hydrolyzing Rb1 to C-K was identiﬁed as Prevo-
tella oris. Whereas, protopanaxatriol type sapo-
nins (ginsenosides Re and Rg1) were hydrolyzed to
20(S)-protopanaxatriol. C-K was shown to in-
crease the cytotoxicity of antineoplastic drugs
(Hasegawa et al., 1995) and to induce apoptosis in
B16-BL6 melanoma cells (Wakabayashi et al.,
1998). And also, the antiproliferative activity of
C-K against tumor cells is primarily due to the
induction of apoptosis via promotion of caspase-3
activity and regulation of apoptosis related pro-
teins, which may lead to the anti-tumor activity
(Suda et al., 2000). Moreover, in parallel with the
antimetastatic eﬀect of oral administration of C-K
after the i.v. injection of colon 26-L5 cells, admin-
istration of C-K before tumor inoculation exerted a
dose-dependent inhibition of liver metastasis (Ha-
segawa et al., 2000a). The pharmacokinetics of C-
K and protopanxatriol were investigated. C-K was
selectively accumulated into the liver and mostly
excreted as bile, but about 24% of C-K was
esteriﬁed with fatty acids in the liver and accumu-
lated in the liver longer than C-K. In case of pro-
topanaxatriol, it was absorbed from the small
intestine into the mesenteric lymphatics followed
by the esteriﬁcation with fatty acids and its
spreading to the organ and excretion as bile (Ha-
segawa et al., 2000b). The fatty acid esteriﬁcation
of intestinal bacterial metabolites of ginsenosides
was found to potentiate the antitumor activity of
the parental metabolites through delay of the
clearance of C-K from the liver and immunosti-
mulation of lymphocyte-mediated tumor cytotox-
icity by the esteriﬁed form (Hasegawa et al., 2000c,
2002). These results deﬁnitely indicate that the
pharmaclogical studies accompanied by metabolic
elucidation of ginsenosides and other biologically
active compounds lead to a better understanding of
the real active ingredients in the body.
Reduction of blood glucose level and improvement
of diabetes treatment by ginsenosides
Diabetes, aﬀecting almost 3% of the world pop-
ulation, is one of the major global health problems
and there is especially high number of incidence in
Figure 4. Chemical structures of ginsenosides with modiﬁed side chain.
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elderly population. It has been shown that the root
of Panax ginseng and other ginseng species possess
anti-hyperglycemic activity in vitro (Kimura et al.,
1980, 1981a, b) and in vivo (Kimura et al., 1981,
1981a, b, 1999; Yokozawa et al., 1985). More than
90% of patients with diabetes have type 2 diabetes,
Figure 5. Metabolic pathway of ginsenosides Rb1, Rb2, Rc and Rd to compound K by intestinal bacterial ﬂora after oral admin-
istraton.
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which is related to aging and diet. Although type 2
diabetes is more common and has serious com-
plications, even reducing life expectancy by 8–
10 years (Astrup and Finer, 2000), most in vivo
animal studies using ginseng have been conducted
in type 1 rather than type 2 diabetes models. Here,
we would like to focus on the eﬀects of ginseng on
type 2 diabetes.
The root of Panax ginseng has been used to
improve glucose homeostasis and insulin sensitivity
(Sonnenborn and Proppert, 1990) and further
clinically to treat type 2 diabetes (Bensky et al.,
1993;Huang, 1999). It has been observed that blood
glucose level falls signiﬁcantly in genetically obese
diabetic mice after treatment with a single 90 mg/kg
of ginseng root extract at an intraperitoneal (i.p.)
dose (Kimura et al., 1999). It has also been dem-
onstrated that 3 g of American ginseng root given
40 min before the test meal signiﬁcantly lowers
blood glucose level in non-diabetic subjects and
type 2 diabetic patients (Vuksan et al., 2000). Oral
administration of Panax ginseng root to diabetic
KKAy mice for 4 weeks reduced blood glucose
levels similar to that of an insulin sensitizer (rosig-
litazone)-treated group (Chung et al., 2001).
Moreover, ginseng therapy for type 2 diabetes ele-
vates mood, improves psychophysical perfor-
mance, and reduces fasting blood glucose and body
weight. A 200 mg dose of ginseng improves gly-
cated hemoglobin, serum lipid, amino-terminal
propeptide concentration, and physical activity.
These observations suggest that ginseng is beneﬁcial
for the people with type 2 diabetes and to prevent
development of diabetes in non-diabetic subjects.
The main component of Panax ginseng is gin-
senosides (ginseng saponins). Ginsenoside Rb2 was
found to be the most eﬀective component of gin-
senosides for streptozotocin-diabetic rats
(Yokozawa et al., 1985). Rats treated with ginse-
noside Rb2 showed a signiﬁcant decrease in blood
glucose level with increased activity of glucokinase
and decreased activity of glucose 6-phosphatase.
Recently, anti-hyperglycemic and antiobese eﬀects
of Panax ginseng berry extract have been demon-
strated, and its major constituent, ginsenoside Re
has been observed (Attele et al., 2002). Treatment
of the berry extract by daily i.p. injection for
12 days in obese diabetic C56BL/6J mice reduced
glucose to levels similar to normal control value;
after treatment the mice also has signiﬁcantly im-
proved glucose tolerance. The improvement of
blood glucose level in the extract-treated ob/ob
mice is associated with a signiﬁcant reduction in
serum insulin level in fed and fasting mice. A
hyperinsulinemic–euglycemic clamp study reveals
more than two-fold increase in the rate of insulin-
stimulated glucose disposal in treated ob/ob mice.
In addition, the extract-treated ob/ob mice lost a
signiﬁcant amount of weight, which was associated
with a signiﬁcant reduction in food intake and very
signiﬁcant increase in energy expenditure and
body temperature.
Anticancer activities of ginsenosides
The main weapons in the war against cancer have
been early detection and surgical removal, radio-
therapy, chemotherapy, and attempts to develop
gene therapy. However, the results are less than
ideal, and the strategy is now changing from
therapeutic approaches to prevention of cancer by
identifying eﬀective natural products as chemo-
preventive agents. One promising candidate with
cancer-preventive eﬀects is Panax ginseng. Its
usefulness in cancer has been shown by extensive
preclinical and epidemiological studies. Here, we
describe the anti-carcinogenic eﬀect of ginseng
based on its diverse mechanisms.
Eﬀect on tumor cell cytotoxicity and diﬀerentiation
Saponin and non-saponin compounds have been
reported to show cytotoxic activities against vari-
ous kinds of cancer cell lines in culture. Major
active components are ginsenoside Rh2, a peculiar
component of red ginseng, and also polyacetyl-
enes, panaxydol, panaxynol and panaxytriol.
Ginseng was found to have the ability to induce
neoplastic cells into normal cells. Ginsenoside Rh2
inhibited the growth and colony forming ability of
Morris hepatoma cells in soft agar suspension
culture, and stimulated serum protein synthesis of
these cells, thus converting the cell characteristics
both functionally and morphologically to those
resembling original normal liver cells, a process
known as ‘‘rediﬀerentiation or reverse transfor-
mation’’ (Odashima et al., 1989). Similarly, ginse-
nosides Rh1 and Rh2 have been shown to cause
diﬀerentiation of F9 teratocarcinoma stem cells via
binding to a steroid receptor (Lee et al., 1993).
Therefore, recent studies on therapy for various
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types of cancers have focused on drugs, which
induce diﬀerentiation of maturation-resistant cells
causing the disease. Furthermore, ginsenoside Rh2
has been found to signiﬁcantly induce B16 cell
diﬀerentiation and to increase melanin synthesis in
B16 cells (Xia and Han, 1996). The cytotoxicity of
natural glycosides from ginseng, semisynthetic
analogues of the genus Betula was evaluated to
elucidate structure–activity relationships. Cyto-
toxic eﬀects of the dammarane glucosides were
inversely proportional both to the number of
sugars attached to the aglycones and to the num-
ber of hydroxyl groups of the aglycones. The type
of side chain and the conﬁguration of the hydroxyl
group at C-3 in aglycones was not found to have a
signiﬁcant inﬂuence on the cytotoxicity (Atopkina
et al., 1999). Ginsenosides Rg3 and Rh2 has been
found to inhibit the proliferation of prostate can-
cer cells, which may be associated with modulation
of three modules of MAP kinases (Kim et al.,
2004). In addition, 20(S)-protopanaxadiol and
ginsenoside Rh2 reduce cell proliferation and in-
crease sub-G1 cells in two cultured intestinal cell
lines, Int-407 and Caco-2, indicating a speciﬁc
structure–function relationshilp for bioactive gin-
senosides in two contrasting intestinal cell types
(Popovich et al., 2004).
Anti-metastatic eﬀects
Generally, primary tumor is not fatal. Instead,
most cancer patients succumb to metastases –
multiple, widespread tumor colonies established
by malignant cells that detach themselves from the
original tumor and travel through the body often
to distant sites. Some invading cells penetrate into
a body cavity or the blood, lymph or spinal ﬂuid
and then are released (Friedberg, 1986). Ginseng
saponin has recently received a great deal of
attention to the eﬀects to inhibit invasion and
metastasis of cancer cells. 20(R)- and 20(S)-ginse-
noside Rg3 was found to possess an ability to in-
hibit the lung metastasis of tumor cells such as
B16-BL-6 melanoma and colon 26M3.1, when
they were orally administered at a dose of 100–
1000 lg/mouse, and the mechanism of their anti-
metastatic eﬀect is supposed to be related to inhi-
bition of the adhesion and invasion of tumor cells,
and also to anti-angiogenesis activity (Mochizuki
et al., 1995). Glucocorticoid receptor-induced
down-regulation of matrix metalloproteinase
(MMP)-9 by panaxadiol (PD) and panaxatriol
(PT) appear to be associated with the reduced
invasive capacity of HT1080, a highly metastatic
human ﬁbrosarcoma cell line (Park et al., 1999).
Multiple administration of ginsenoside Rb2 after
the intravenous inoculation of B16-BL6 melanoma
cells resulted in a signiﬁcant inhibition of tumor-
associated angiogenesis responsible for the inhibi-
tion of lung tumor metastasis (Sato et al., 1994).
Ginsenoside Rb2 has been reported to inhibit
invasion to the basement membrane via MMP-2
suppression in some endometrial cancers such as
HHUA and HEC-1-A cells, and is supposed to be
used as a medicine for inhibition of secondary
spreading of uterine endometrial cancers
(Fujimoto et al., 2001). It was shown that ginse-
noside Rg3 inhibited experimental pulmonary
metastasis by highly metastatic mouse melanoma
B16FE7 cells, which was mediated by inhibiting
the 1-oleoyl-lysophosphatidic acid (LPA)-trig-
gered rise of intracellular Ca+2 (Shinkai et al.,
1996). While these results suggest the usefulness of
ginsenoside Rg3 in preventing cancer spread, fur-
ther studies on in vivo will be necessary to clarify
anti-metastatic eﬀects of ginseng.
Anticarcinogenic activities and synergistic eﬀects
in combination with chemical therapeutic agents
Several investigations were carried out to evaluate
the inhibitory or preventive eﬀects of ginseng on
carcinogenesis induced by various chemical car-
cinogens. The prolonged administration of Korean
red ginseng extract inhibited the incidence and the
proliferation of tumors induced by 7,12-dimeth-
ylbenz(a)anthracene (DMBA), urethane, and
aﬂatoxin B1 (Yun et al., 1983). The chemopre-
ventive potential of ginseng was evaluated using
DMBA-induced skin tumorigenesis (papilloma-
genesis) in male Swiss albino mice, and there was a
marked reduction not only in tumor incidence but
also in cumulative tumor frequency at the
initiation phase of tumorigenesis, while a little
reduction at the promotional stage, suggesting the
anti-carcinogenic activities of ginseng (Kumar,
1993). Ginsenosides Rg3 and Rg5 were found to
show statistically signiﬁcant reduction of lung tu-
mor incidence in the newly established 9 weeks’
medium-term anti-carcinogenicity test model of
lung tumors in mice, and ginsenoside Rh2 showed
a tendency of decreasing the incidence, indicating
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them to be active anti-carcinogenic compounds
(Yun et al., 2001). Subsequent studies have con-
ﬁrmed that Panax ginseng C. A. Meyer cultivated
in Korea is a non-organ speciﬁc cancer preventive
against human cancers and the anticarcinogenicity
or human cancer preventive eﬀects is due to gin-
senosides Rg3, Rg5 and Rh2 (Yun, 2003). The
inhibitory eﬀects of ginseng on the development of
1,2-dimethylhydrazine (DMH)-induced aberrant
crypt foci (ACF) in the colon were investigated in
rats. Dietary administration of red ginseng in
combination with DMH suppresses colon carci-
nogenesis in rats associated partly with inhibition
of cell proliferation, acting on ACF in the colonic
mucosa (Fukushima et al., 2001). In addition,
anti-carcinogenic eﬀect of red ginseng on the
development of liver cancer induced by diethylni-
trosamine (DEN) in rats was identiﬁed in pre-
ventive and curative groups (Wu et al., 2001).
More recently, it has been reported that less gly-
cosylated protopanaxadiol derivatives are eﬀective
in cancer prevention and some oleanane-type
pentacyclic triterpenoid compounds show anti-
carcinogenic activities in two-stage anti-cancer
promotion experiments in vitro and in vivo (Shi-
bata, 2001). Ginsenoside Rh2 has been described
to have diverse eﬀects on the expression of the
transformed phenotype in BALB/c3T3 cells, and
augments the metastatic potential in an experi-
mental metastasis assay (Tatsuka et al., 2001). The
estrogenic potential of American ginseng extract
to induce the expression of pS2, an estrogen-reg-
ulated gene, was evaluated in breast cancer cell
lines MCF-7, T-47D and BT-20. It is found that
American ginseng exhibits estrogen-like eﬀects on
estrogen receptor-positive breast cancer cells by
inducing pS2 expression, suggesting that it may
play a protective role against breast cancer (Duda
et al., 1996). It is further supported by the fact that
American ginseng inhibits breast cancer cell
growth by transcriptional activation of the p21
gene, a universal cell cycle inhibitor, independent
of p53 (Duda et al., 2001). It is also reported that
concurrent use of American ginseng extract and
breast cancer therapeutic agents results in a sig-
niﬁcant suppression of cancer cell growth, sug-
gesting its synergistic eﬀects on breast cancer
therapeutics (Duda et al., 1999). Compound K, an
intestinal bacterial metabolite derived from pro-
topanaxadiol saponin, has been found to show
anti-inﬂammatory eﬀects by inhibiting TPA-in-
duced COX-2 expression, which may contribute to
its antitumor-promoting eﬀects on mouse skin
carcinogenesis (Lee et al., 2005).
Antitumor activities
It has been reported that an inhibitory eﬀect of
oral administration of ginsenoside Rh2 on tumor
growth in nude mice bearing human ovarian
cancer cells (HRA), resulting in a remarkable
retardation of the tumor growth. In particular,
tumor growth in mice treated with 15, 30 and
120 lM of ginsenoside Rh2 was signiﬁcantly
inhibited, compared to that in CDDP (cis-diam-
inedichloroplatinum) (II)-treated mice as well as
in untreated mice (Tode et al., 1993). Further
investigation showed that p.o. but not i.p. treat-
ment with ginsenoside Rh2 resulted in induction
of apoptosis in the tumor in addition to aug-
mentation of the natural killer activity in spleen
cells from tumor-bearing nude mice, suggesting
that an evaluation of the treatment of recurrent
or refractory ovarian tumors is warranted (Nak-
ata et al., 1998).
Induction of apoptosis
Apoptosis is responsible for pathological mecha-
nism related to human diseases such as cancer,
autoimmune disease, viral infection and neurode-
generative disorder (Thompson, 1995). Ginseno-
side Rh2 has been shown to arrest cell cycle at the
G1 phase and to prolong the S phase (Fujikawa-
yammamoto et al., 1987; Lee et al., 1996). It was
reported that ginsenoside Rh2 induced apoptosis
through protein kinase C in human neuroblastoma
SK-N-BE and rat glioma C6Bu-1 cells (Kim et al.,
1999a–d). In addition, ginsenoside Rh2 has been
shown to induce apoptosis independently of Bcl-2,
Bcl-xL, or Bax in C6Bu-1 cells (Kim et al., 1999a–
d). In a parallel study, it was found that ginseno-
side Rh2-induced cell death was mediated by the
generated reactive oxygen species and activation of
caspase pathway in a Bcl-xL-independent manner.
These reports demonstrate that the induction of
apoptosis by ginseng can be one of its anti-car-
cinogenic mechanisms. In structure and apoptosis
relationship, the presence of sugars in proto-
panaxadiol and protopanxatriol aglycone struc-
tures has been found to reduce the potency to
induce apoptosis in the human leukemia (THP-1)
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cell line and alternately alter membrane integrity
(Popovich et al., 2002).
Inhibitory activities of 20(S)-ginsenoside Rg3
on multi-drug resistance (MDR)
One of the major side eﬀects to the eﬀective
treatment of human malignancies is the acquisition
of broad anti-cancer drug resistance by tumor
cells. This phenomenon has been termed ‘‘multi-
drug resistance (MDR)’’. Therefore, development
of new modulator for inhibition of drug resistance
is required. MDR inhibitory activity was
determined by measuring cytotoxicity to MDR
cells using multi-drug resistant human ﬁbrocarci-
noma KB V20C, which is resistant to 20 nM of
vincristine and expresses high level of mdr1 gene.
20(S)-Ginsenoside Rg3 (Rg3), saponin of red gin-
seng, was found to have the most potent inhibitory
activity on MDR and its ID50 (dose for 50%
inhibition) was 8.210)5 M. In cytotoxicity assay,
ginsenoside Rg3 did not aﬀect the growth of nor-
mal cells (Park et al., 1996). More recently, it was
shown that the mechanism of Pgp (P-glycoprotein)
inhibition and in vivo eﬃcacy by Rg3 has been
elucidated as follows by us (Kim et al., 2003).
Inhibition of rhodamine 123 eﬄux
by 20(S)-ginsenoside Rg3
Rhodamine 123 acts as a good substrate for
MDR-associated Pgp and agents that block Pgp
have been found to increase the retention of
rhodamine 123 in MDR cells. Therefore, drug-
sensitive and -resistant cells were exposed to rho-
damine 123 at the various concentrations of
verapamil or Rg3 for 30 min and retention of
rhodamine 123 was determined. Treatment of KB
cells with Rg3 did not aﬀect retention of rhoda-
mine 123, but treatment of KBV20C cells signiﬁ-
cantly increased the accumulation of rhodamine
123 in a dose-dependent manner (Figure 6). Rg3
did not increase eﬄux of rhodamine 123 eﬀectively
at lower doses, however Rg3 was more potent than
verapamil in modulating MDR function at the
higher concentrations than 200 lM of Rg3, as re-
ﬂected by higher rhodamine 123 retention in the
resistant cells. Since incubation of 320 lM of Rg3
for 30 min with KBV20C cells signiﬁcantly in-
creased eﬄux of rhodamine 123 without losing
cells integrity in PBS buﬀer, subsequent time
course experiment used 320 lM of Rg3. These re-
sults clearly demonstrated that Rg3 reversed MDR
in KBV20C cells speciﬁcally and eﬀectively in a
dose dependent manner.
Inhibition of [3H]-vinblastine eﬄux by Rg3
To ascertain further that Rg3 can enhance the
accumulation of chemotherapeutic agents,
KB or KBV20C cells were incubated with [3H]-
vinblastine for the indicated time in the presence of
either verapamil or Rg3, and the accumulated [
3H]-
vinblastine in KB or KBV20C cells was subse-
quently counted. In KB cells, Rg3 or verapamil did
not exhibit any diﬀerence from the group without
any treatment in [3H]-vinblastine accumulation
Figure 6. Increase of rhodamine 123 retention by Rg3.
Rhodamine 123 retention in resistant KBV20C but not in
parent KB cells. KB or KBV20C cells were incubated at
37 C for 24 h, and were resuspended in fresh media
containing rhodamine 123, and further incubated at 37 C for
30 min. After washing, the cells were incubated again in fresh
media containing Rg3, or verapamil at the indicated
concentrations at 37 C for 30 min. Cells were then removed
and re-suspended in PBS, and analyzed by ﬂow cytometry.
The median ﬂuorescence was used as a quantitative measure
of intracellular ﬂuorochrome accumulation and hence an
indicator for Pgp inhibition. The vertical bar represents
mean±SD of the two experiments in triplicate. If vertical
bars are not apparent, the size of the SD was close to zero.
The average ﬂuorescence values in KB and KBV20C without
Rg3 or verapamil were 6777 and 44.5, respectively.
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(data not shown). In KBV20C cells, 80 lM of Rg3
had amarginal eﬀect in reversingMDR, however at
320 lM [3H]-vinblastine accumulation was en-
hanced by approximately four-fold after 30 min
incubation at 37 C. In comparison, verapamil at
100 lMaugmented drug accumulation by two-fold
demonstrating that 320 lM of Rg3 inhibited drug
eﬄux more potently than 100 lM of verapamil
(Figure 7). This result conﬁrmed that Rg3 is an
eﬀective MDRmodulator. Also potentiation of the
accumulation of drug inMDRcells, but not in drug-
sensitive cells, indicate that the MDR reversing ef-
fects ofRg3 were not due to the toxicity of Rg3 itself.
Inhibition of [3H]-azidopine binding to Pgp by Rg3
Since Rg3 did not aﬀect MDR1 gene expression,
MDR reversal by Rg3 might be due to inhibition
of drug binding to Pgp by Rg3. To demonstrate
competitive inhibition of drug binding by Rg3,
photoaﬃnity labeling of Pgp with [3H]- azidopine
was used. Treatment of 100 lM of Rg3 completely
inhibited binding of [3H]- azidopine to Pgp dem-
onstrating that Rg3 competes with [
3H]- azidopine
for binding to Pgp (Figure 8).
In vivo eﬃcacy
For in vivo evaluation of Rg3, a standard P388
murine leukemia model was used. In a preliminary
experiment, DOX (doxorubicin) alone or a com-
bination of a wide range of doses (2.5, 10, 40,
80 mg/kg) of the Rg3 with 4 mg/kg of DOX was
administered to mice (6/group) implanted with
P388/DOX tumors. The result demonstrated that
administration of a combination of 2.5 mg/kg of
Rg3 and 4 mg/kg of DOX did not result in sig-
niﬁcant increase in life span of mice or mice
weight, and administration of 80 mg/kg of Rg3, by
itself, did not produce any signiﬁcant diﬀerence in
life span compared with the vehicle control. In
addition, combination treatment with 4 mg/kg
DOX and 80 mg/kg Rg3 produced no signiﬁcant
increase in life span of mice than combination
treatment with 4 mg/kg DOX and 40 mg/kg Rg3
(data not shown). Therefore mice were treated
with a combination of 4 mg/kg DOX plus 10 or
40 mg/kg Rg3. When mice were treated with a
combination of 4 mg/kg DOX plus 10 mg/kg of
the Rg3, a signiﬁcant increase in life-span (p<0.01)
was observed. Increasing the dose of Rg3 upto
Figure 7. Increase of [3H]-vinblastine accumulation by Rg3.
[3H]-vinblastine accumulation in KBV20C cells was deter-
mined after incubation with 26 lM [3H]-vinblastine and the
appropriate modulator for the indicated time. After the indi-
cated time, the cells were washed with ice-cold PBS twice, sol-
ubilized in 0.2% Triton X-100 in 10 mM phosphate buﬀer
(pH 7.4), harvested, and then counted. The vertical bar repre-
sents mean±SD of triplicate determinations.
Figure 8. Inhibition of [3H]-azidopine labeling of P-glycopro-
tein by Rg3. To determine inhibition of [
3H]-azidopine bind-
ing to Pgp, resistant KBV20C plasma membrane proteins
were incubated with 0.2 lM [3H]-azidopine in the absence or
presence of Rg3 or verapamil at the indicated concentrations
and cross-linked by UV irradiation. Photolabeled membrane
proteins were analyzed by SDS-PAGE and visualized by
autoradiography.
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40 mg/kg did not extend life span any further
(Figure 9). These results suggest that the increase
of DOX cytotoxicity by Rg3 in vivo is modulated
through the interaction of the Rg3 with Pgp.
Further clinical trial in reversal of Pgp-associated
MDR is highly feasible.
In addition, it is also reported that quas-
ipanaxatriol, 20(S)-protopanaxatriol, ginsenoside
Rh2 and compound K, metabolic ﬁnal product of
protopanaxadiol saponin, greatly enhanced the
cytotoxicity of the anti-cancer drugs in P388/
ADM cells (adriamycin-resistant P388 leukemia
cells) (Hasegawa et al., 1995). The reversal of
daunomycin resistance in P388/ADM by quas-
ipanaxatriol with double bond introduced at C-20
of protopanaxatriol was found to show the eﬀec-
tive accumulation of the drugs mediated by the
daunomycin-eﬄux blockage. Furthermore, a re-
cent similar result showed that protopanaxatriol
ginsenoside has a chemosensitizing eﬀect on Pgp-
mediated MDR cells by increasing the intracellular
accumulation of drugs through direct interaction
with Pgp at the azidopine site (Choi et al., 2003).
These results suggest that further clinical trial of
ginseng components in reversal of Pgp-associated
MDR is highly feasible.
Antihypertensive eﬀects of ginsenosides
High blood pressure is associated with decreased
life expectancy and increased risk of stroke, coro-
nary heart disease and other end-organ disease
such as renal failure. Ginseng contains active
compounds normalizing blood pressure. The eﬀect
of a certain drug on the blood pressure can be
analyzed by investigating the eﬀect of the drug on
the smooth muscle of blood vessel. It is well
established that blood vessel smooth muscle tone is
regulated by the available intracellular Ca2+ con-
centration, which in turn is profoundly inﬂuenced
by interaction of the cellular membrane and sar-
coplasmic reticulum in the smooth muscle. It is
found that both protopanxatriol and proto-
panaxadiol saponins inhibit Ca2+ binding to the
cellular membrane, but protopanaxatriol is
approximately 180% more potent than proto-
panaxadiol ginsenosides (Lee, 1980). It was re-
ported that ginseng induced no signiﬁcant change
in blood pressure in those subjects with normal
blood pressure, but had a normalizing eﬀect on the
subjects with abnormal blood pressure
(Yammamoto, 1992). It has recently been reported
that vasodilation and protective eﬀect of ginseno-
side Rg1 against free radical injury might be re-
lated to enhanced synthesis and release of NO
(Nitric Oxide), demonstrating the usefulness of
ginseng in treatment of pulmonary and systemic
hypertension (Gillis et al., 1993). The detailed
mechanism and evidence of anti-hypertensive ef-
fect of ginseng are as follows.
Endothelium-dependent vasorelaxation
Endothelium plays an important role in regulating
vascular tone by releasing several vasoactive
autacoids including prostacyclin, endothelium-de-
rived relaxing factor (EDRF) and endothelium-
derived hyperpolarizing factor (EDHF) (Vane
et al., 1990). EDRF has been identiﬁed as NO,
which is produced from L-arginine by NOS (nitric
oxide synthase) (Palmer et al., 1988). NO relaxes
blood vessel mostly by stimulating soluble
guanylyl cyclase, which leads to an increased
production of cGMP in vascular smooth muscle
(Rapoport and Murad, 1983). Ginsenosides have
been found to lower blood pressure in a dose-
dependent manner in rats at doses of 10–100 mg/
kg, which is mediated by release of endothelium-
derived NO, enhancing the accumulation of
cGMP (Kim et al., 1994). Recently, it is also
reported that ginseng can improve the vascular
endothelial dysfunction in patients with hyper-
Figure 9. Increase of the survival of mice implanted intraperi-
toneally into P388/DOX murine leukemia tumor cells by Rg3
in combination with DOX. Multidrug resistant P388/DOX
cells (2106 cells/0.1 ml) were inoculated intraperitoneally
into BDF1 female mice. Compounds were administered intra-
peritoneally at every 3 days after tumor implantation. The re-
sults represent the survival percentage versus days after tumor
implantation. Control, r; DOX 4 mg/kg, n; DOX 4 mg/
kg+Rg3 10 mg/kg, m; DOX 4 mg/kg+Rg3 40 mg/kg, .
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tension possibly through increasing synthesis of
NO. Protopanaxatriol and its puriﬁed ginsenosides
Rg1 and Re caused endothelium-dependent relax-
ation, which is associated with the formation of
cGMP. In contrast, protopanaxadiol or ginseno-
sides Rg1 and Re did not aﬀect vascular tone or
production of cGMP in rat aorta. Moreover, gin-
senosides Rg1 and Re were less eﬀective endothe-
lium-dependent vasodilators than total
ginsenosides and protopanaxatriol (Kang et al.,
1995). Ginsenoside Rg3 is one of protopanaxadiol
group of red ginseng, steamed and dried ginseng.
Present ﬁndings indicate that ginsenoside Rg3
eﬀectively stimulates the NO formation in endo-
thelial cells, which accounts for the endothelim-
dependent relaxation and production of cGMP in
the rat aorta. The ginsenoside Rg3-induced endo-
thelium-dependent relaxation was markedly
inhibited by a non-selective K+ channel blocker,
but not by an ATP-sensitive K+ channel blocker
(Kim et al., 1999a–d). These ﬁndings show that
ginsenoside Rg3 activates tetraethylammonium-
sensitive K+ channels in endothelial cells, which
presumably leads to an inﬂux of Ca2+ and the
subsequent activation of the endothelial NOS
(eNOS) (Kim et al., 1999a–d). In order to inves-
tigate the eﬀect of red ginseng on the blood pres-
sure, the change of blood pressure and heart rate
after intravenous injection of red ginseng was
studied in the conscious normotensive and one-
kidney, one-clip Goldblatt hypertensive rats.
Experimental evidence indicates that the NO-
releasing eﬀect of red ginseng is, like other NO
donors, partly contributed to hypotensive eﬀects
(Jeon et al., 2000). Clinical study has been per-
formed to estimate the eﬀect of Korean red gin-
seng on vascular endothelial cell dysfunction in
patients with hypertension. To assess the function
of the vascular endothelial cell, changes of forearm
blood ﬂow to infusion of acetylcholine, sodium
nitroprusside and bradykinin in incremental doses
were measured by venous occlusion plethysmog-
raphy. In ginseng-treated hypertensive group,
forearm blood ﬂows at the highest dose of ace-
tylcholine and bradykinin were signiﬁcantly higher
than those of the non-treated hypertensive group.
It was found that Korean red ginseng could im-
prove the vascular endothelial dysfunction in pa-
tients with hypertension possibly through
increasing the NO synthesis (Sung et al., 2000).
These results support that ginseng shows phar-
macological activities on circulatory diseases
including hypertension. In another study, ginse-
nosides Rb1 and Re has been found to decrease
cardiac contraction in adult rat ventricular myo-
cytes, which may be mediated in part through in-
creased NO production (Scott et al., 2001). Based
upon the previously published research data, sev-
eral reviews underscore the potential beneﬁt eﬀects
of ginseng on cardiovascular diseases and
emphasizes the necessity for more rigorous sys-
temic investigation (Zhou et al., 2004). When
electrophysiological eﬀects of ginsenosides were
examined on action potential and membrane
currents recorded from isolated guinea pig ven-
tricular myocytes, inhibition of L-type Ca+2 cur-
rent and enhancement of the delayed rectiﬁer K+
current appear to be associated with ginsenoside
Re (Bai et al., 2003). Eﬀect of notoginsenoside R1,
active component of Panax notoginseng, was
found to increase the ﬁbrinolytic potential in cul-
tured human pulmonary artery smooth muscle
cells by increasing the production of tissue-type
plasminogen activator, suggesting the eﬀect of
notoginsenoside R1 in the treatment of cardio-
vascular diseases (Zhang et al., 1997).
Antiatherosclerosis and antiplatelet eﬀects
Endothelial cell damage is considered to be the
initial step in the genesis of thrombosis and arte-
riosclerosis, the common precursors of cardiovas-
cular disorders. Platelet hyperfunction such as
enhanced platelet aggregation associated with
overproduction of thromboxane A2 (TXA2), a
potent platelet aggregative and vasoconstrictive
substance, has been frequently encountered in
patients with cardiovascular thrombotic diseases.
Prostaglandin I2 (PGI2), a potent anti-platelet
aggregative and vasodilatatory substance
produced in vascular walls, is also reported to less
synthesize in patients with atherosclerotic changes
than normal subjects. Panaxynol was found to
markedly inhibit the aggregation of platelets in-
duced by collagen, arachidonic acid and platelet
activating factor (PAF), while ginsenosides had no
signiﬁcant eﬀect on the aggregation. It is suggested
that panaxynol is the most potent anti-platelet
agent in ginseng and its mechanism of action is
chieﬂy due to the inhibition of thromboxane
formation (Teng et al., 1989). In addition, it was
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reported that panaxynol inhibited the aggregation,
release and thromboxane formation in rabbit
platelets, while ginsenosides Ro, Rg1 and Rg2
suppressed only the release (Kubo et al., 1990).
Continually, it was also demonstrated that ginse-
noside Rg1 inhibited platelet activation induced by
TXA2 through inhibition of TXA2-induced Ca
2+
mobilization, and ginsenoside Rg3 induced TXA2-
induced platelet aggregation. Ginsenoside Rc was
shown to stimulate in vitro PGI2 formation by
cultured rat vascular smooth muscle cells through
enhanced gene expression of cyclooxygenase
(Hirai, 1999). These results suggest that ginseno-
sides Rg1 and Rg3, which have anti-platelet and
anti-atherosclerotic eﬀects, may have clinical po-
tential for the prevention and the treatment of
certain thrombotic and atherosclerotic disorders.
Moreover, American ginseng extract was proved
to be associated with the inhibition of thrombin-
induced endothelin release due to NO release
(Yuan et al., 1999). This result suggests that
American ginseng may play a therapeutic role in
facilitating the hemodynamic balance of vascular
endothelial cells.
Conclusions
For a long time, ginseng has been one of the
highly valued herbs in the East. Recently, many
clinical trials using ginseng have been undertaken
in the West as well as in the East area. Here, we
have summarized diverse pharmacological and
physiological eﬀect of ginsenosids on the various
diseases such as diabetes, cancer and cardiovas-
cular diseases. However, although there have
been lots of evidence suggesting that ginseng can
be useful for the treatment of various diseases,
we still have a long way to go. First of all, a lot
of experiments reported have been performed in
animal models instead of human beings. There-
fore, a large-scale, controlled clinical study is
needed to validate these results and apply to
human beings. Secondly, there is still little evi-
dence how ginsenosides and so on can be eﬀec-
tive in the molecular levels. Understanding of
molecular regulation of ginsenosides will be
necessary to apply ginseng clinically, and also to
ﬁnd out new therapeutic eﬀect of ginseng.
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